The US Food and Drug Administration (FDA) has rescinded its marketing denial order (MDO) affecting 14 Turning Point Brands products, admitting that “relevant information that was not adequately assessed”. The company has responded by putting on hold a legal action against the agency.
In a letter to the vaping manufacturer and distributor, the FDA said the randomised trials and cross-sectional surveys that Turning Point Brands (TPB) presented in its premarket tobacco product applications (PMTAs) required “further review”.
Get access to premium content that is normally only available for subscribers.
For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.
LATEST ALERTS
